Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD PhD, Jan A. Burger, MD PhD, Kristie A. Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Ying Luan, PhD, Emily A. Liu, PhD, James P. Dean, MD PhD, Susan M. O'Brien, MD

Blood (2018) 132 (Supplement 1): 3133.

https://doi.org/10.1182/blood-2018-99-110847

Published: 2018

Journal Articles

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Jeff Sharman, MD, Anna Marina Liberati, MD, Rodrigo Santucci Silva, MD, Igor Aurer, MD PhD, Jeffery Robbins, MS, Julie Ann Rosenberg, MD, Tahira Khan, MD MS, Ann Alcasid

Blood (2018) 132 (Supplement 1): 394.

https://doi.org/10.1182/blood-2018-99-111248

Published: 2018

Journal Articles

Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLL TM Real-World Registry

Anthony R. Mato, MDMSCE, Jacqueline C. Barrientos, MD MS, Danielle M. Brander, MD, John M. Pagel, MD PhD, Meghan Gutierrez, Karen Kadish, MSN, Brian Tomlinson, MPA, Nilanjan Ghosh, MD PhD, Nick Giafis, PhD, David Ipe, Sandhya Upasani, Murali Sundaram, MBA, PhD, Lucille Ferrante, MD, Carlos Amaya-Chanaga, MD, Reethi Iyengar, PhD, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 4425.

https://doi.org/10.1182/blood-2018-99-110566

Published: 2018

Journal Articles

Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study

Jeff Sharman, MD, Shaum Kabadi, PhD MPH, Jamyia Clark, MPH, E Susan Amirian, PhD MS, David J. Andorsky, MD

Blood (2018) 132 (Supplement 1): 4163.

https://doi.org/10.1182/blood-2018-99-118848

Published: 2018

Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Blood (2018) 132 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2018-99-112989

Published: 2018

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, Bruce Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, Uwe Hahn, Eliza Hawkes, Cyrus Khan, Izidore S. Lossos, MD, Gerardo Musuraka, Monica Tani, Umberto Vitolo, Sam Yuen, Mikkel Z Oestergaard, Surya Chitra, Michael Wenger, Tina Nielsen, Gila Sellam, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 2969.

https://doi.org/10.1182/blood-2018-99-116678

Published: 2018

Journal Articles

Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL TM Real-World Registry

Jeff Sharman, MD, Jacqueline C. Barrientos, MD MS, Danielle M. Brander, MD, John M. Pagel, MD PhD, Meghan Gutierrez, Karen Kadish, MSN, Brian Tomlinson, MPA, Nilanjan Ghosh, MD PhD, Nick Giafis, PhD, David Ipe, Sandhya Upasani, Murali Sundaram, MBA, PhD, Lucille Ferrante, MD, Carlos Amaya-Chanaga, MD, Reethi Iyengar, PhD, Anthony R. Mato, MD MSCE

Blood (2018) 132 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2018-99-110562

Published: 2018

Journal Articles

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Susan O’Brien, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd

Blood (2018) 131 (17): 1910–1919.

https://doi.org/10.1182/blood-2017-10-810044

Published: 2018

Includes: Supplemental data

Journal Articles

Management of Elderly Patients with Diffuse Large B-Cell Lymphoma in a Network of Community Oncology Practices in the United States

John M Burke, MD, Jenny L Black-Shinn, PhD, Jamyia Clark, MPH, Jennifer Frytak, PhD, Janet Espirito, PharmD, BCOP, Jeff Sharman, MD

Blood (2016) 128 (22): 4215.

https://doi.org/10.1182/blood.V128.22.4215.4215

Published: 2016

Journal Articles

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Jeff Sharman, MD, Matthew Davids, MD, Charles Michael Farber, MD PhD, David L. Grinblatt, MD, Neil E. Kay, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Chadi Nabhan, MD MBA, FACP, Kristen Sullivan, MBA, CCRA, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 5941.

https://doi.org/10.1182/blood.V128.22.5941.5941

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Hervé Tilly, MD PhD, Franck Morschhauser, Nancy L Bartlett, MD, Jeff Sharman, MD, Corinne Haioun, MD PhD, Kathryn S. Kolibaba, Andy Chen, DO, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Elicia Penuel, PhD, Calvin Lee, Gilles A. Salles

Blood (2016) 128 (22): 1853.

https://doi.org/10.1182/blood.V128.22.1853.1853

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Andres Forero-Torres, MD, Kathryn S. Kolibaba, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Calvin Lee, Jeff Sharman, MD

Blood (2016) 128 (22): 1856.

https://doi.org/10.1182/blood.V128.22.1856.1856

Published: 2016

Journal Articles

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Inhye E Ahn, MD, Charles Michael Farber, MD PhD, Matthew Davids, MD, David L. Grinblatt, MD, Nicole Lamanna, MD, Anthony R. Mato, MDMSCE, Chadi Nabhan, MD MBA, FACP, Pavel Kiselev, PhD, Arlene S. Swern, PhD, E. Dawn Flick, RPh, MPH, ScD, Shriya Bhushan, PharmD, Kristen Sullivan, MBA, CCRA, Jeff Sharman, MD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 3581.

https://doi.org/10.1182/blood.V128.22.3581.3581

Published: 2016

Journal Articles

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Susan M. O'Brien, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD PhD, Jan Burger, MD PhD, Kristie Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Jeffrey Jones, MD MPH, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Ying Luan, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, John C. Byrd, MD

Blood (2016) 128 (22): 233.

https://doi.org/10.1182/blood.V128.22.233.233

Published: 2016

Journal Articles

Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL

Susan O'Brien, MD, Samantha Jaglowski, MD MPH, John C. Byrd, MD, Rajat Bannerji, MD PhD, Kristie Blum, MD, Christopher P. Fox, MBChB, PhD, Richard R. Furman, MD, Peter Hillmen, Thomas J. Kipps, MD, Marco Montillo, MD, Jeff Sharman, MD, Sam Suzuki, MS, MBA, Danelle James, MD MAS, Alvina D. Chu, MD, Steven Coutre, MD

Blood (2015) 126 (23): 4153.

https://doi.org/10.1182/blood.V126.23.4153.4153

Published: 2015

Journal Articles

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Jeff Sharman, Michael Hawkins, Kathryn Kolibaba, Michael Boxer, Leonard Klein, Meihua Wu, Jing Hu, Steve Abella, Chris Yasenchak

Blood (2015) 125 (15): 2336–2343.

https://doi.org/10.1182/blood-2014-08-595934

Published: 2015

Includes: Supplemental data

Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Blood (2013) 122 (15): 2539–2549.

https://doi.org/10.1182/blood-2013-06-507947

Published: 2013

Includes: Supplemental data

Journal Articles

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.

Eric D. Jacobsen, MD, Ranjana H. Advani, MD, Yasuhiro Oki, MD, Jeff Sharman, MD, Steven M. Horwitz, MD, Andres Forero-Torres, MD, Owen A. O'Connor, MD, PhD, Andrei R. Shustov, MD, Tanya Siddiqi, MD, Laurie E. Grove, PA-C, Nancy L. Bartlett, MD

Blood (2012) 120 (21): 2746.

https://doi.org/10.1182/blood.V120.21.2746.2746

Published: 2012

Journal Articles

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma

Nathan H Fowler, MD, Ranjana H Advani, MD, Jeff Sharman, MD, Sonali M. Smith, MD, Jesse McGreivy, MD, Lori Kunkel, MD, Vina Troung, Cathy Zhou, Thomas E. Boyd, MD

Blood (2012) 120 (21): 156.

https://doi.org/10.1182/blood.V120.21.156.156

Published: 2012

Journal Articles

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

Steven E. Coutre, MD, John P. Leonard, MD, Richard R. Furman, MD, Jacqueline C. Barrientos, MD, Sven de Vos, MD, PhD, Ian W. Flinn, MD, PhD, Marshall T. Schreeder, MD, Nina D. Wagner-Johnston, MD, Jeff Sharman, MD, Thomas E. Boyd, MD, Nathan H Fowler, MD, Leanne M. Holes, Brian J. Lannutti, PhD, Dave M. Johnson, Langdon L Miller, MD, Thomas M. Jahn, MD/PhD

Blood (2012) 120 (21): 191.

https://doi.org/10.1182/blood.V120.21.191.191

Published: 2012

NARROW

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLL TM Real-World Registry

Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL TM Real-World Registry

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Management of Elderly Patients with Diffuse Large B-Cell Lymphoma in a Network of Community Oncology Practices in the United States

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only